Immune checkpoint inhibitors, such as anti-PD1/PDL1 antibodies, have achieved satisfactory results in the treatment of several cancer types, and Hao Zhang et al. showed that the expression of lncRNAs in GBM can be used to assess responsiveness to immune checkpoint therapies 56, 57. The gene discussed is CD274; the disease is cancer.